Results 51 to 60 of about 312,196 (386)

Omalizumab as a Provoking Factor for Venous Thromboembolism

Drug Target Insights, 2019
A 43-year-old man with a history of severe extrinsic allergic asthma treated with once-monthly omalizumab (600 mg) for the last 15 months. He presented to the emergency room with a 2-week history of right lower limb pain and chest pleuritic pain ...
Crhistian-Mario Oblitas, Francisco Galeano-Valle, Laura Vela-De La Cruz, Jorge Del Toro-Cervera, Pablo Demelo-Rodríguez   +4 more
doaj   +1 more source

Hospital volume and outcomes for acute pulmonary embolism: Multinational population based cohort study [PDF]

, 2019
[Objectives] To evaluate the association between experience in the management of acute pulmonary embolism, reflected by hospital case volume, and mortality.[Design] Multinational population based cohort study using data from the Registro Informatizado de
Bikdeli, Behnood, de Miguel-Diez, Javier, Jara-Palomares, Luis, Jimenez, David, Lobo, Jose Luis, Monreal, Manuel, Muriel, Alfonso, Quezada, Andres, RIETE investigators,, Ruiz-Artacho, Pedro, Yusen, Roger D   +10 more
core   +2 more sources

Direct Oral Anticoagulants (DOACs) are Non-Inferior to Vitamin K Antagonists for Patients Undergoing Transcatheter Aortic Valve Replacement with Indications of Anticoagulation

Reviews in Cardiovascular Medicine, 2022
Background: The best anticoagulation choice for patients undergoing transcatheter aortic valve replacement (TAVR) with indications of oral anticoagulation (OAC) remains uncertain.
Jia Wang, Feng-Ying Zhang, Li Liu, Mang-Mang Pan, Chi Zhang, Jin Chen, Yuan Bian, Hou-Wen Lin, Zhi-Chun Gu   +8 more
doaj   +1 more source

Direct Oral Anticoagulants for the Treatment of Unusual-Site Venous Thrombosis: An Update

Pharmaceutics
Direct oral anticoagulants (DOACs) have emerged as the preferred oral anticoagulant therapy for patients with deep vein thrombosis of the lower extremities and pulmonary embolism. DOACs offer several advantages over vitamin K antagonists, including fixed
Anabel Franco-Moreno, Elena Madroñal-Cerezo, Ana Martínez-Casa-Muñoz, Judith Ortiz-Sánchez, Cristina Lucía Ancos-Aracil   +4 more
doaj   +1 more source

Tranexamic Acid Administered During Off-Pump Coronary Artery Bypass Graft Surgeries Achieves Good Safety Effects and Hemostasis

Frontiers in Cardiovascular Medicine, 2022
BackgroundTranexamic acid (TXA) administered during off-pump coronary artery bypass (OPCAB) surgeries has achieved good blood control in small cohorts.
Enshi Wang, Xin Yuan, Yang Wang, Weinan Chen, Xingtong Zhou, Shengshou Hu, Su Yuan   +6 more
doaj   +1 more source

American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Blood Advances, 2019
BACKGROUND Venous thromboembolism (VTE) is a common source of perioperative morbidity and mortality. OBJECTIVE These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about preventing VTE in ...
D. Anderson, G. P. Morgano, Carole Bennett, F. Dentali, C. Francis, D. Garcia, S. Kahn, Maryam Rahman, A. Rajasekhar, F. Rogers, M. Smythe, K. Tikkinen, A. Yates, Tejan Baldeh, S. Balduzzi, J. Brożek, I. Ikobaltzeta, H. Johal, I. Neumann, W. Wiercioch, J. Yepes-Nuñez, H. Schünemann, P. Dahm   +22 more
semanticscholar   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Blood Advances, 2018
BACKGROUND Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism. OBJECTIVE These
A. Cuker, G. Arepally, B. Chong, D. Cines, A. Greinacher, Y. Gruel, L. Linkins, Stephen B Rodner, S. Selleng, T. Warkentin, A. Wex, R. Mustafa, R. Morgan, N. Santesso   +13 more
semanticscholar   +1 more source

PATHOGENETIC APPROACHES AND WAYS OF PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN TRAUMA PATIENTS

International Journal of Medicine and Medical Research, 2018
Background. The study of thromboembolic complications prevention in trauma patients, who underwent surgery, is presented in the research. Objective. Patients were examined in the Department of Traumatology of Ternopil Municipal Hospital. The first group,
L. Yu. Ivashchuk
doaj   +1 more source

Renal Vein Thrombosis in Idiopathic Thrombocytopenic Purpura [PDF]

Journal of Clinical and Diagnostic Research, 2020
Renal Vein Thrombosis (RVT) is thrombotic occlusion of one or both main renal veins, resulting in acute or chronic kidney disease. The clinical presentation of RVT depends on the degree of venous occlusion.
Subodh Kumar Das, Debashis Routray, Pradeep Narayan Sahoo, Sukanto Kishore Das, Sambit K Mohanty   +4 more
doaj   +1 more source